Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
PHD Course in Experimental Medicine, University of Pavia, 27100, Pavia, Italy.
J Endocrinol Invest. 2021 May;44(5):891-904. doi: 10.1007/s40618-021-01506-7. Epub 2021 Feb 9.
COVID-19 is now a worldwide pandemic. Among the many extra-pulmonary manifestations of COVID-19, recent evidence suggested a possible occurrence of thyroid dysfunction.
The Aim of the present review is to summarize available studies regarding thyroid function alterations in patients with COVID-19 and to overview the possible physio-pathological explanations.
The repercussions of the thyroid of COVID-19 seem to be related, in part, with the occurrence of a "cytokine storm" that would, in turn, induce a "non-thyroidal illness". Some specific cytokines and chemokines appear to have a direct role on the hypothalamus-pituitary-thyroid axis. On the other hand, some authors have observed an increased incidence of a destructive thyroiditis, either subacute or painless, in patients with COVID-19. The hypothesis of a direct infection of the thyroid by SARS-Cov-2 stems from the observation that its receptor, ACE2, is strongly expressed in thyroid tissue. Lastly, it is highly probable that some pharmaceutical agents largely used for the treatment of COVID-19 can act as confounding factors in the laboratory evaluation of thyroid function parameters.
COVID-19 现已在全球范围内流行。在 COVID-19 的许多肺外表现中,最近的证据表明甲状腺功能障碍可能发生。
本综述的目的是总结关于 COVID-19 患者甲状腺功能改变的现有研究,并概述可能的生理病理解释。
COVID-19 对甲状腺的影响似乎部分与“细胞因子风暴”的发生有关,而细胞因子风暴反过来又会引起“非甲状腺疾病”。一些特定的细胞因子和趋化因子似乎对下丘脑-垂体-甲状腺轴有直接作用。另一方面,一些作者观察到 COVID-19 患者破坏性甲状腺炎(亚急性或无痛性)的发生率增加。SARS-CoV-2 直接感染甲状腺的假设源于这样一种观察,即其受体 ACE2 在甲状腺组织中强烈表达。最后,用于治疗 COVID-19 的一些药物很可能是甲状腺功能参数实验室评估中的混杂因素。